13F Holdings
中文EN

TWST Twist Bioscience Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1581280 · Fiscal year ends 09/30

Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY22.0%
TTM net income YoY-67.6%
TTM EPS YoY-60.0%
Revenue 3-yr CAGR23.3%
Net income 3-yr CAGR—

Margins

Gross margin52.4%
Operating margin-30.4%
Net margin-28.3%
FCF margin-19.4%
EBITDA margin-24.7%

Returns

ROE-19.1%
ROA-14.8%
ROIC (approx.)-34.2%
Asset turnover0.52x

Leverage & solvency

Liabilities / assets20.8%
Debt / equity0.00x
Current ratio5.86x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.32x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue10.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-09-30FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30
Income statement
Revenue$459.43M$376.57M$312.97M$245.11M$203.56M
Cost of revenue$218.63M$185.57M$179.62M$155.38M$119.33M
Gross profit$240.80M$191.00M$133.35M$89.73M$84.23M
R&D expense$71.84M$80.28M$90.85M$106.89M$120.31M
SG&A expense$301.21M$246.98M$218.40M$189.74M$212.95M
Operating income-$139.46M-$136.26M-$220.83M-$217.16M-$234.78M
Interest expense——$29,000$5,000$80,000
Pretax income-$129.80M-$76.95M-$208.17M-$203.47M-$228.27M
Income tax$406,000$719,000$560,000$1.15M-$10.41M
Net income-$130.20M-$77.67M-$208.73M-$204.62M-$217.86M
EBITDA-$112.97M-$111.41M-$189.40M-$187.85M-$218.26M
EPS (basic)-2.08-1.30-3.60-3.60-4.04
EPS (diluted)-2.08-1.30-3.60-3.60-4.04
Weighted avg. shares (diluted)62.62M59.81M58.02M56.88M53.88M
Balance sheet
Cash & equivalents$533.99M$183.05M$229.13M$289.28M$380.26M
Short-term investments$47.91M$49.38M$50.08M$49.94M$126.28M
Receivables$70.19M$57.02M$34.90M$44.06M$40.29M
Inventory$46.41M$28.31M$24.08M$32.06M$39.31M
Current assets$737.22M$332.97M$346.78M$424.26M$596.48M
PP&E, net$122.32M$102.28M$102.52M$131.83M$139.44M
Goodwill$82.19M$82.19M$85.81M$85.81M$85.81M
Intangibles$34.16M$13.43M$14.48M$54.48M$59.74M
Total assets$1.12B$641.86M$614.32M$776.40M$961.38M
Current liabilities$125.81M$91.41M$71.01M$73.32M$90.66M
Short-term debt————$0
Total liabilities$233.79M$168.90M$141.63M$152.97M$171.99M
Shareholders' equity$888.02M$472.96M$472.69M$623.43M$789.38M
Shares outstanding67.81M60.63M58.88M57.56M56.52M
Cash flow statement
Operating cash flow-$41.43M-$47.63M-$64.09M-$142.47M-$124.39M
Capital expenditure$47.58M$28.00M$5.08M$27.78M$101.86M
Free cash flow-$89.01M-$75.63M-$69.17M-$170.25M-$226.24M
Investing cash flow-$53.09M-$24.76M-$3.07M$50.61M-$232.93M
Financing cash flow$446.68M$28.54M$6.89M$911,000$270.53M
Depreciation & amortization$26.48M$24.85M$31.43M$29.31M$16.51M
Stock-based compensation$69.86M$64.46M$50.92M$30.28M$79.66M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.